Edgewise reports Q3 2026 results, data supports Phase 3 plan
Edgewise Therapeutics reported Q3 2026 results and dosed the first patient in its Phase 2 EQUINOX-HFpEF trial. Additionally, positive CIRRUS-HCM Part D results for EDG-7500 may support a Phase 3 trial initiation by year-end 2026, keeping the pipeline on target.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed